|
Characteristic
|
Uniform distribution (DMVD < 10) (n = 187)
|
Uneven distribution (DMVD > 10) (68)
|
Statistics
|
P
|
|---|
|
Age (years)
|
51.86 ± 9.55
|
52.04 ± 9.84
|
-0.138
|
0.890
|
|
Menopause
| | |
0.389
|
0.572
|
|
Postmenopausal
|
88
|
35
| | |
|
Premenopausal
|
99
|
33
| | |
|
Family history
| | |
0.012
|
1.000
|
|
No
|
174
|
63
| | |
|
Yes
|
13
|
5
| | |
|
Diameter
|
2.21 ± 0.95
|
2.67 ± 1.31
|
-3.061
|
0.002
|
|
Quadrant
| | |
5.680
|
0.224
|
|
Areolar
|
3
|
2
| | |
|
Inner upper
|
39
|
6
| | |
|
Inner lower
|
17
|
8
| | |
|
Outer lower
|
32
|
11
| | |
|
Outer upper
|
96
|
41
| | |
|
Patterns of enhancement
| | |
179.854
|
0.000
|
|
Homogeneous
|
77(41.2%)
|
5(7.4%)
| | |
|
Heterogeneous
|
110(58.8%)
|
11(16.2%)
| | |
|
Peripheral
|
0(0%)
|
52(76.5%)
| | |
|
Difference of MVD (Edge - Center)
|
1.29 ± 5.03
|
15.60 ± 4.27
|
-20.873
|
0.000
|
|
Histological grade
| | |
2.105
|
0.349
|
|
I
|
50
|
13
| | |
|
II
|
120
|
46
| | |
|
III
|
17
|
9
| | |
|
Cancer thrombosis
| | |
1.891
|
0.204
|
|
Negative
|
140
|
45
| | |
|
Positive
|
47
|
23
| | |
|
Nodal metastasis
| | |
0.174
|
0.777
|
|
Negative
|
88
|
30
| | |
|
Positive
|
99
|
38
| | |
|
Number of metastatic nodes
|
2.91 ± 5.97
|
6.21 ± 9.42
|
-3.302
|
0.001
|
|
Clinical stage
| | |
18.458
|
0.002
|
|
I
|
46(24.6%)
|
13(19.1%)
| | |
|
IIA
|
60(32.1%)
|
16(23.5%)
| | |
|
IIB
|
64(34.2%)
|
20(29.4%)
| | |
|
IIIA
|
11(5.9%)
|
7(10.3%)
| | |
|
IIIB
|
2(1.1%)
|
5(7.4%)
| | |
|
IIIC
|
4(2.1%)
|
7(10.3%)
| | |
|
IV
|
0(0%)
|
0(0%)
| | |
|
ER
| | |
18.731
|
0.000
|
|
Negative
|
57(30.5%)
|
41(60.3%)
| | |
|
Positive
|
130(69.5%)
|
27(39.7%)
| | |
|
PgR
| | |
26.314
|
0.000
|
|
Negative
|
48(25.7%)
|
41(60.3%)
| | |
|
Positive
|
139(74.3%)
|
27(39.7%)
| | |
|
HER2
| | |
9.786
|
0.003
|
|
Negative
|
167(89.3%)
|
50(73.5%)
| | |
|
Positive
|
20(10.7%)
|
18(26.5%)
| | |
|
Ki67
| | |
10.827
|
0.001
|
|
Negative (<14%)
|
120(64.2%)
|
28(41.2%)
| | |
|
Positive (>14%)
|
67(35.8%)
|
40(58.8%)
| | |
|
P53 (%)
|
32.08 ± 31.58
|
29.90 ± 33.94
|
0.479
|
0.633
|
|
Clinicopathological subtypes
| | |
42.300
|
0.000
|
|
Luminal A
|
102(54.5%)
|
17(25.0%)
| | |
|
Luminal B (Ki67+)
|
44(23.5%)
|
8(11.8%)
| | |
|
Luminal B (HER2+)
|
14(7.5%)
|
8(11.8%)
| | |
|
HER2 overexpression
|
6(3.2%)
|
10(14.7%)
| | |
|
TNBC
|
21(11.2%)
|
25(36.8%)
| | |
|
Operation
| | |
0.819
|
0.485
|
|
Mastectomy
|
166
|
63
| | |
|
Tumorectomy
|
21
|
5
| | |
|
Chemotherapy program
| | |
17.357
|
0.004
|
|
Not performed
|
0(0%)
|
2(2.9%)
| | |
|
CMF
|
2(1.1%)
|
0(0%)
| | |
|
CAF or AC
|
60(32.1%)
|
12(17.6%)
| | |
|
CEF or EC
|
43(23.0%)
|
19(27.9%)
| | |
|
T or TC or TP
|
59(31.6%)
|
17(25.0%)
| | |
|
TAC or A-T
|
23(12.3%)
|
18(26.5%)
| | |
|
Radiotherapy
| | |
2.012
|
0.160
|
|
Not performed
|
104
|
31
| | |
|
Performed
|
83
|
37
| | |
|
Endocrine therapy
| | |
38.443
|
0.000
|
|
Not performed
|
27(14.4%)
|
35(51.5%)
| | |
|
TAM
|
99(52.9%)
|
20(29.4%)
| | |
|
LHRH
|
13(7.0%)
|
5(7.4%)
| | |
|
AI
|
48(25.7%)
|
8(11.8%)
| | |
|
Targeted therapy
| | |
0.116
|
1.000
|
|
Not performed
|
183
|
67
| | |
|
Performed
|
4
|
1
| | |
|
Overall survival
|
99.5%
|
85.3%
|
24.308
|
0.000
|
|
Event
|
1
|
10
| | |
|
Deaths
|
1
|
9
| | |
|
Lost to Follow-up
|
0
|
1
| | |
|
Median survival time
|
54.0
|
54.0
|
14.885
|
0.000
|
|
Disease-free survival
|
99.5%
|
67.6%
|
62.030
|
0.000
|
|
Event
|
1
|
22
| | |
|
Local recurrence
|
0
|
1
| | |
|
Contralateral breast cancer
|
0
|
4
| | |
|
Lung metastasis
|
0
|
2
| | |
|
Hepatic metastasis
|
0
|
5
| | |
|
Brain metastasis
|
0
|
3
| | |
|
Multi-organ
|
1
|
6
| | |
|
Lost to Follow-up
|
0
|
1
| | |
|
Disease-free survival
|
54.0
|
31.9
|
47.546
|
0.000
|
|
Follow-up time
| | |
0.384
|
0.701
|
|
Median
|
23.0
|
22.0
| | |
|
Range
|
12-58
|
12-59
| | |
